Insider Trading April 17, 2026 05:34 PM

Alector Accounting Chief Sells Small Stake as Firm Sees Strategic Pivot and Analyst Upgrade

Principal accounting officer Grace Wong-Sarad disposes of $4,823 in ALEC shares while BTIG raises rating to Buy amid programmatic shift

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
ALEC

Grace Wong-Sarad, Principal Accounting Officer at Alector, Inc. (NASDAQ: ALEC), sold 1,820 shares on April 16, 2026, for $2.65 per share, a transaction valued at $4,823. The sale was made under a Rule 10b5-1 trading plan adopted on September 5, 2025. The stock is trading at $2.57, below InvestingPro's Fair Value estimate, even after a 177% gain over the past year. Separately, BTIG upgraded Alector from Neutral to Buy with a $6.00 price target, citing a strategic emphasis on therapeutics that use blood-brain barrier shuttle domains following an unsuccessful frontotemporal dementia trial.

Alector Accounting Chief Sells Small Stake as Firm Sees Strategic Pivot and Analyst Upgrade
ALEC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Grace Wong-Sarad sold 1,820 Alector shares on April 16, 2026, at $2.65 per share, totaling $4,823.
  • After the sale, Wong-Sarad directly owns 104,645 shares; the sale was made under a Rule 10b5-1 plan adopted on September 5, 2025.
  • BTIG upgraded Alector from Neutral to Buy with a $6.00 price target, citing a strategic shift toward blood-brain barrier shuttle domain therapeutics following an unsuccessful frontotemporal dementia trial.

Transaction details

Grace Wong-Sarad, who serves as Principal Accounting Officer for Alector, Inc. (NASDAQ: ALEC), executed a sale of 1,820 common shares on April 16, 2026. The shares changed hands at $2.65 per share, producing a total transaction value of $4,823. The disposition was carried out pursuant to a Rule 10b5-1 trading plan that Wong-Sarad adopted on September 5, 2025.


Post-transaction ownership

Following the sale, Wong-Sarad directly holds 104,645 shares of Alector. The transaction details and the continued ownership position are consistent with the filing information released by the company.


Market context and valuation note

At the time of the reported sale, Alector's shares were trading at $2.57, which the report notes is below InvestingPro's Fair Value estimate. The commentary highlights that the company has nevertheless posted an impressive 177% gain over the past year. Investors and analysts monitoring valuation metrics may see the current trading level relative to the Fair Value estimate as an indicator that the stock could be undervalued, based on the InvestingPro assessment.


Analyst action and strategic focus

In a separate development, BTIG upgraded Alector from a Neutral rating to a Buy rating and set a price target of $6.00. BTIG's rationale, as reported, centers on the company's strategic realignment toward developing therapeutics incorporating blood-brain barrier shuttle domains. The firm said this direction removes a key source of uncertainty following an unsuccessful frontotemporal dementia trial.


Resources for investors

For readers seeking deeper financial analysis, the report references a Pro Research Report available on InvestingPro that provides additional detail on Alector's financial position and outlook.


Contextual note

The reported insider sale was executed under an established trading plan, and the company has simultaneously been the subject of analyst reassessment tied to its therapeutic development strategy. The facts presented here are limited to the disclosed transaction, post-sale ownership, current trading price relative to InvestingPro's Fair Value estimate, and the BTIG upgrade with its stated rationale.

Risks

  • The company recently reported an unsuccessful frontotemporal dementia trial, which introduces clinical and development uncertainty for its programs.
  • The insider sale, while executed under a Rule 10b5-1 plan, represents a reduction in holdings that some investors may interpret as signal risk for sentiment around the stock.
  • Valuation remains contested: the shares trade below InvestingPro's Fair Value estimate despite a 177% gain over the past year, leaving uncertainty around near-term price direction.

More from Insider Trading

Alignment Healthcare CEO John Kao Offloads Over $6M in Stock Amid Leadership Transition Jun 12, 2026 Corpay Executive Disposes of $1.6M in Shares Amid Strategic Expansion Jun 12, 2026 APi Group Director Franklin Offloads $84.16 Million in Shares Amid Strategic Expansion Jun 12, 2026 Soluna Holdings' Chief Accounting Officer Offloads $27,250 in Preferred Shares Amid Market Volatility Jun 12, 2026 Microvast CTO Wenjuan Mattis Executes $5,175 Stock Sale Jun 12, 2026